Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases

Clinical Infectious Diseases

Volumn 33, Issue 11, 2001, Pages 1914-1921

  Coghlan, Michael E ^a   Sommadossi, Jean Pierre ^b   Jhala, Nirag C ^c   Many, Wickliffe J ^a   Michael, S Saag ^a   Johnson, Victoria A ^a,d  

^a Departments of Medicine   (United States)

^b Pharmacology and Toxicology   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; PANCREATITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEATOSIS; SYMPTOM; TEACHING HOSPITAL; WEIGHT REDUCTION;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LIVER; RADIOGRAPHY, ABDOMINAL; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035577396     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323783     Document Type: Article

References (26)

1. Lactic acidosis complicating the acquired immunodeficiency syndrome
2. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
3. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
4. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
5. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
6. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion
7. Lactic acidosis associated with stavudine administration: A report of 5 cases
8. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
9. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
10. Mitochondrial toxicity of antiviral drugs
11. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
12. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program
13. Riboflavin to treat nucleoside analogue-induced lactic acidosis
14. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
15. Diseases of the mitochondrial DNA
16. Hyperlactatemia in 20 patients receiving NRTI combination regimens
17. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens
18. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
19. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides
20. Effect of anti-HIV 2'-β-fluoro-2',3'-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production
21. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
22. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-βD-arabinofuranosyl)-5-iodouracil in human liver cells
23. Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax)
24. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells
25. Randomized trial of continued indinavir (IDV)/ZDV/3TC vs. switch to IDV/ddI/d4T or IDV/ddI/d4T + hydroxyurea in patients with viral suppression
26. The effects of hydroxyurea or placebo combined with efavirenz, didanosine, and stavudine in treatment naive and experienced patients: Preliminary 24 week results from the 3d study